Cellectar Biosciences, Inc. logo

Cellectar Biosciences, Inc.

NASDAQ:CLRB

Overview | Financials
Company Name Cellectar Biosciences, Inc.
Symbol CLRB
Currency USD
Price 2.06
Market Cap 73,848,734
Dividend Yield 0%
52-week-range 1.82 - 4.45
Industry Biotechnology
Sector Healthcare
CEO Mr. James V. Caruso
Website https://www.cellectar.com

An error occurred while fetching data.

About Cellectar Biosciences, Inc.

Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study in patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia and

Related Stocks

Aytu BioPharma, Inc. logo

Aytu BioPharma, Inc.

AYTU

2.29 USD

Sio Gene Therapies Inc. logo

Sio Gene Therapies Inc.

SIOX

0.415 USD

Landos Biopharma, Inc. logo

Landos Biopharma, Inc.

LABP

22.93 USD

Financials

Numbers are in millions USD

Numbers are in millions USD